Featured Research

from universities, journals, and other organizations

Experimental Therapy May Lead To Better Multiple Sclerosis Treatment

Date:
January 23, 2001
Source:
NIH/National Institute Of Allergy And Infectious Diseases
Summary:
A new therapy effectively treats a disease similar to multiple sclerosis (MS) in monkeys, and the approach could soon be tested against MS and other autoimmune diseases in humans. The therapy's promising results, reported by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), will be published in the February 1 issue of the Journal of Immunology.

A new therapy effectively treats a disease similar to multiple sclerosis (MS) in monkeys, and the approach could soon be tested against MS and other autoimmune diseases in humans. The therapy's promising results, reported by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), will be published in the February 1 issue of the Journal of Immunology.

Related Articles


"Current treatments for MS broadly suppress the immune system and can cause toxic side effects," says senior study author Michael Lenardo, M.D., of NIAID's Laboratory of Immunology. "This treatment, called antigen-specific immunotherapy, specifically targets the immune system's T cells that cause the disease. Presumably, it would not lead to such side effects."

Autoimmune diseases such as rheumatoid arthritis, type 1 diabetes and MS affect approximately 5 percent of the U.S. population. Directly and indirectly, they cost the U.S. economy more than $100 billion per year. "Immune-mediated diseases are a major cornerstone of the NIAID research effort," says Anthony S. Fauci, M.D., director of NIAID. "Efforts such as Dr. Lenardo's hold great promise for developing new treatments for individuals with autoimmune diseases."

MS is a paralyzing disease that affects nerves in the brain and spinal cord, disturbing speech, vision and movement. MS primarily strikes young adults, most often women who live in northern latitudes. The disease is caused by a malfunction in the immune system: certain white blood cells called T cells mistakenly attack myelin sheaths, protective coverings that surround the signal-carrying fibers of nerve cells.

Antigen-specific immunotherapy is based on a discovery by Dr. Lenardo and his colleagues that T cells exposed to small amounts of the proteins making up the myelin sheaths are stimulated to attack the sheaths. But T cells exposed to large amounts of the same proteins will undergo a pre-programmed "self-destruct" sequence. (In fact, T cells exposed to large amounts of any antigen -- a substance that provokes them to attack -- will self-destruct.) Therefore, introducing large amounts of myelin proteins into the body should remove the problematic T cells and halt the disease, Dr. Lenardo explains.

"The therapy is counter-intuitive; one might think it would be like pouring gasoline on a fire," Dr. Lenardo says. But the self-destruct sequence actually protects the body from having too many active T cells, which can themselves be toxic. "Like any potent weapon, you want to control how much is deployed," Dr. Lenardo explains. "The immune system doesn't let your T cells grow uncontrolled and kill you. In this case, adding more antigen smothers the fire."

Dr. Lenardo and his colleagues first injected nine male marmoset monkeys with just enough myelin proteins to stimulate their T cells to attack myelin sheaths, inducing a disease very similar to MS in humans. Three monkeys then received additional large doses of myelin proteins, three received moderate doses, and three received nothing. The monkeys were observed for 105 days. All three of the untreated monkeys showed clinical symptoms of the disease. In contrast, none of the monkeys in the large-dose group showed symptoms. In the moderate-dose group, two of the three showed symptoms, but those symptoms were significantly delayed.

Magnetic resonance images of the animals' brains revealed severe damage to the myelin sheaths in two of the untreated monkeys and one of the moderate-dose monkeys. Minor damage did occur in the large-dose group, indicating the disease process had not been completely thwarted although it had been greatly suppressed. The treatment appeared to cause no adverse side effects. Researchers at the National Institute of Neurological Disorders and Stroke assisted with the experiment.

Dr. Lenardo and his colleagues are investigating how the therapy works against other autoimmune diseases in laboratory mice. One such disease under investigation is myasthenia gravis, a paralyzing condition affecting children that is caused when the immune system mistakenly attacks the receptors on muscle cells that receive nerve impulses.


Story Source:

The above story is based on materials provided by NIH/National Institute Of Allergy And Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute Of Allergy And Infectious Diseases. "Experimental Therapy May Lead To Better Multiple Sclerosis Treatment." ScienceDaily. ScienceDaily, 23 January 2001. <www.sciencedaily.com/releases/2001/01/010123075527.htm>.
NIH/National Institute Of Allergy And Infectious Diseases. (2001, January 23). Experimental Therapy May Lead To Better Multiple Sclerosis Treatment. ScienceDaily. Retrieved November 21, 2014 from www.sciencedaily.com/releases/2001/01/010123075527.htm
NIH/National Institute Of Allergy And Infectious Diseases. "Experimental Therapy May Lead To Better Multiple Sclerosis Treatment." ScienceDaily. www.sciencedaily.com/releases/2001/01/010123075527.htm (accessed November 21, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Milestone Birthdays Can Bring Existential Crisis, Study Says

Milestone Birthdays Can Bring Existential Crisis, Study Says

Newsy (Nov. 21, 2014) Researchers find that as people approach new decades in their lives they make bigger life decisions. Video provided by Newsy
Powered by NewsLook.com
Ebola: Life Without School in Guinea

Ebola: Life Without School in Guinea

AFP (Nov. 21, 2014) Following the closure of schools and universities in Guinea because of the Ebola virus, students look for temporary work or gather in makeshift classrooms to catch up on their syllabus. Duration: 02:14 Video provided by AFP
Powered by NewsLook.com
UN Says It Will Scale Up Its Ebola Response

UN Says It Will Scale Up Its Ebola Response

AFP (Nov. 20, 2014) UN Resident Coordinator David McLachlan-Karr and WHO representative in the country Daniel Kertesz updated the media on the UN Ebola response on Wednesday. Duration: 00:51 Video provided by AFP
Powered by NewsLook.com
Takata Offers "sincerest Condolences" To Victims of Malfunctioning Airbag

Takata Offers "sincerest Condolences" To Victims of Malfunctioning Airbag

Reuters - US Online Video (Nov. 20, 2014) U.S. Congress hears from a victim and company officials as it holds a hearing on the safety of Takata airbags after reports of injuries. Rough Cut (no reporter narration). Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins